Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Avista Q4 EPS $0.71 Beats $0.67 Estimate

Avista (NYSE:AVA) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.67 by 5.97 percent. This is a 16.47 percent decrease over earnings of $0.85 per share from the same period
byBill Haddad
February 23, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Avista (NYSE:AVA) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.67 by 5.97 percent. This is a 16.47 percent decrease over earnings of $0.85 per share from the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Sorrento Therapeutics shares are trading high following FDA clearance of IND for Abivertinib in metastatic castrate resistant prostate cancer (mCRPC)

By Ragothaman Srinivasan
Today, 8:52 PM
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug application (IND) of Abivertinib (Fujovee) for patients with metastatic castrate resistant prostate cancer (mCRPC) in the Phase 2 MAVERICK clinical study.

SRNE

Read More

Earnings Preview For PDS Biotechnology

By Benzinga Insights
Today, 8:52 PM
PDS Biotechnology (NASDAQ:PDSB) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement. Analysts estimate that PDS Biotechnology will report an earnings per share (EPS) of $-0.24.

PDSB